07/25/2025 05:25
Bureau Veritas Expands its Footprint in New Strongholds Through Acquisitions in Cybersecurity, Nuclear and Transition Services

Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces three targeted acquisitions in the fast-growing sectors of Cybersecurity, Nuclear, and Transition Services as the company creates new portfolio strongholds. Bureau Veritas has signed an agreement with Dornier Group to acquire its Dornier Hinneburg subsidiary in Germany to strengthen its nuclear industry capabilities. It also signed agreements to acquire Institute For Cyber Risk (IFCR) to establis...

07/08/2025 17:15
Azumah Resources: Committed to Ghana’s Future

Azumah Resources Ghana Limited (“Azumah”) is grateful to the Government of Ghana for ensuring that the rule of law has been fairly applied for many years in Ghana. We are confident that this Government will continue in that stead ensuring investors have confidence when investing in Ghana and ensure that they are not subject to arbitrary and unfair treatment. Azumah is focused on moving forward with the development of the Black Volta Gold Mine in the Upper West. John Mason, Spokesperson for Az...

07/25/2025 05:30
Bureau Veritas: Robust Organic Revenue Growth and Strong Margin Increase in H1 2025 as the LEAP | 28 Strategy Execution Accelerates; Confirmed 2025 Outlook

Bureau Veritas (BOURSE:BVI): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250724086759/en/Hinda Gharbi, CEO Bureau Veritas H1 2025 key figures1 › Revenue of EUR 3,192.5 million in the first half of 2025, up 5.7% year-on-year and up 6.7% organically (with 6.2% organic growth in Q2 2025), › Adjusted operating profit of EUR 491.5 million, up 8.8% versus EUR 451.9 million in H1 2024, representing an adjusted operating margin of 15.4...

07/03/2025 10:02
Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model

The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no causal treatment for tinnitus, there is a high medica...

07/10/2025 12:05
NETSCOUT Advances AI-Driven Network Operations for TM Forum’s NeuroNOC: The Self-Healing Network Brain Catalyst Project

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT), a leading provider of observability, AIOps, cybersecurity, and DDoS attack protection solutions, today announced its recent participation in TM Forum’s NeuroNOC Catalyst, an innovation project at DTW Ignite 2025, which set records for having the most Communication Service Providers and countries represented at a DTW Ignite event. TM Forum is a global alliance of telco and tech companies, leading the industry in defining the building blocks for new operatin...

07/10/2025 12:14
Barilla Group Appoints Oddone Incisa as CFO

Barilla Group is pleased to announce the appointment of Oddone Incisa as our new Chief Financial Officer, effective September 15, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710908942/en/Oddone Incisa - Chief Financial Officer, Barilla Group Oddone brings over 25 years of global leadership in finance and risk management, with executive roles, including CFO and CEO positions across Europe and the Americas. His track record...

07/28/2025 07:00
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models—including target-humanized, immune-humanized, transgenic, and immunodeficient mice—alongside a full suite of preclinical services su...